Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer-Reference-Cited by-同舟云学术

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer

Published:2019-12-19 Issue:2 Volume:11 Page:369-378
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Grambozov Brane¹,Wolf Frank¹,Kaiser Julia¹,Wass Romana²,Fastner Gerd¹,Gaisberger Christoph¹,Rettenbacher Lukas¹,Studnicka Michael²,Pirich Christian³,Sedlmayer Felix¹⁴,Zehentmayr Franz¹⁴^ORCID

Affiliation:

1. Department of Radiation OncologyParacelsus Medical University, SALK Salzburg Austria

2. Department of PneumologyParacelsus Medical University, SALK Salzburg Austria

3. Department of Nuclear MedicineParacelsus Medical University, SALK Salzburg Austria

4. radART ‐ Institute for Research and Development on Advanced Radiation TechnologiesParacelsus Medical University Salzburg Austria

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13276

Reference36 articles.

1. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung Cancer

2. Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study

3. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value-Added Nanocellulose Valorized from Fruit Peel Waste for Potential Dermal Wound Healing and Tissue Regenerative Applications;Regenerative Engineering and Translational Medicine;2024-07-19

2. Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity;Cancer Treatment Reviews;2024-03

3. Factors that Influence the Need to Start Adaptive Radiotherapy;Journal of Immunotherapy and Precision Oncology;2024-02-01

4. Evaluation of variables predicting PFT changes for lung cancer patients treated on a prospective 4DCT-ventilation functional avoidance clinical trial;Radiotherapy and Oncology;2023-10

5. Dosimetric comparison of four radiotherapy techniques for stage III non‑small cell lung cancer;Oncology Letters;2023-06-27